FRXX yields 666666.67% · JNJ yields 2.13%● Live data
📍 FRXX pulled ahead of the other in Year 1
Combined, FRXX + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FRXX + JNJ for your $10,000?
Forecross Corporation designs and develops software to re-deploy and sustain legacy applications on the Internet. The company offers XML solutions that enable enterprises to make legacy applications e-Ready; and IT applications protection solution. Its automated migration solution includes convert/ADSOTM, which converts ADSO dialogs into functionally equivalent, ready-to-test, CICS command level COBOL programs; and convert/IDMS-DCTM that converts IDMS/DC programs into functionally equivalent, ready-to-test CICS command level programs. The company's migration solution also comprises convert/IDMS-DBTM, which converts IDMS/DB programs, data and databases into functionally equivalent, ready-to-test applications supporting ANSI standard SQL environment; convert/CSPTM that converts CSP applications into functionally equivalent, ready-to-test CICS command level COBOL programs; and convert/VSAMTM, which converts VSAM programs, data and files into functionally equivalent, ready-to-test applications supporting any ANSI standard SQL environments. Forecross Corporation was founded in 1982 and is based in San Francisco, California.
Full FRXX Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.